Wandercraft raises $75M to scale exoskeletons, humanoids

Wandercraft, a French robotics company, has secured $75 million in Series D funding to advance the commercialization and scaling of its innovative exoskeleton and humanoid robot technologies. The funding will support the launch of Eve, a self-balancing personal exoskeleton designed to provide upright motion and walking independence for individuals with severe mobility impairments, with commercialization targeted as early as 2026. Additionally, Wandercraft aims to expand clinical adoption of its rehabilitation system Atalante X and develop Calvin-40, an industrial-grade humanoid robot intended for physically demanding tasks. The company’s technology leverages AI refined through extensive simulations and real-world use, enhancing natural walking motion and mobility for users. Wandercraft is conducting clinical trials for Eve at the James J. Peters VA Medical Center in New York and will soon start another at the Kessler Institute for Rehabilitation in New Jersey, focusing on safety and effectiveness for spinal cord injury patients. A notable milestone was achieved when Kevin Piette